Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 2
Development Phase
1
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
0 competitors in Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
View Full LandscapeTarget Indication
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Clinical Trial
NCT05445843Last updated: 2/14/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Multiple Sclerosis
Solid Tumors
Chronic Obstructive Pulmonary Disease
Influenza
Swine-Origin Influenza A H1N1 Virus